About Us
Real-time Quotes & News
Market Analysis
Trading Platform
Terms
Promotion
FAQ
Contact
繁
简
EN
繁
简
EN
Promotion
FAQ
Contact
Open Account
Contact Us

[CR Double-Crane: Hydroxycobalamin Injection Receives Clinical Trial Approval] CR Double-Crane announced that it recently received the "Drug Clinical Trial Approval Notice" for its hydroxycobalamin injection issued by the National Medical Products Ad

2025-12-29

[CR Double-Crane: Hydroxycobalamin Injection Receives Clinical Trial Approval] CR Double-Crane announced that it recently received the "Drug Clinical Trial Approval Notice" for its hydroxycobalamin injection issued by the National Medical Products Administration. The notice indicates that hydroxycobalamin injection is suitable for the treatment of metabolic disorders in children with methylmalonic acidemia with or without homocysteineemia. The company received the acceptance notice on October 22, 2025, and the "Drug Clinical Trial Approval Notice" on December 25, 2025. As of the date of this announcement, the company's cumulative R&D investment in this drug is RMB 13,058,100 (unaudited).

Other News
2025-12-29

Domestic News: 1. Wang Yi met separately with the foreign ministers of Cambodia and Thailand in Yunnan. A ceasefire was reached between Cambodia and Thailand thanks to the joint efforts of China and other parties. 2. Ministry of Finance: Next year,

Domestic News: 1. Wang Yi met separately with the foreign ministers of Cambodia and Thailand in Yunnan. A ceasefire was reached between Cambodia and Thailand thanks to the joint efforts of China and other parties. 2. Ministry of Finance: Next year, fiscal spending will be expanded, and a special action to boost consumption will be implemented in depth. 3. Ministry of Finance: Next year, funds will continue to be allocated to support the trade-in of old consumer goods. Next year, fiscal policy will promote employment and income growth for residents. 4. Hong Kong Financial Secretary Paul Chan: Actively explore new opportunities, including commodity trading and international gold trading. 5. Xiaomi co-founder Lin Bin announced a massive share reduction plan: the total amount will not exceed US$2 billion, stating that the proceeds will mainly be used to establish an investment fund. International News: 1. CME Group raises margin requirements for all metal commodities. 2. Trump: The Thai-Cambodian conflict will end; the US is the "real United Nations." 3. Silver prices repeatedly hit new highs; Musk: This is not good; silver is essential in many industrial production processes. 4. US-Ukraine Presidential Talks – ① Zelensky stated that the US and Ukraine have reached a 100% agreement on security guarantees, while Trump claimed it is 95% complete. ② Trump spoke with Putin before meeting with Zelensky. ③ Zelensky: We discussed a national referendum, which could be used for the peace plan. ④ Trump: The key territorial issue between Russia and Ukraine has not yet been agreed upon.
2025-12-29

According to Hong Kong Stock Exchange filings, as of December 19, Citigroup's long position in ZTE Corporation's (00763.HK) H shares decreased from 8.79% to 7.60%.

According to Hong Kong Stock Exchange filings, as of December 19, Citigroup's long position in ZTE Corporation's (00763.HK) H shares decreased from 8.79% to 7.60%.
Open Account
Demo Account
Contact Us
About Us Real-time Quotes & News Market Analysis
 Trading Platform Market Analysis Promotion Terms Promotion FAQ Contact
Copyright © 2025 Aspire Global Company Limited. All Rights Reserved.
Terms of Use and Privacy
Disclaimer

Disclaimer: ASPIRE is not responsible for the content of any analysis, advice, comment, suggestion, research report or market data in this website and links to third-party websites or resources. All the information mentioned above only represents the view of corresponding author. ASPIRE cannot and does not warrant the accuracy, validity, timeliness or completeness of any such information. You should conduct individual assessments and other proper research to make their investment decisions. The materials and information contained in this website are provided for reference only and do not constitute or form an offer, invitation, solicitation or investment advice or recommendation to acquire or dispose of any investment products or services. The price of any financial instruments described in this website may fall as well as rise. Past performance should not be taken as an indication of future performance. The risk disclosure statements do not purport to disclose or discuss all of the risks and other significant aspects of any financial instruments mentioned in this website. You should make your own appraisal of the risk and should consult to the extent necessary your own legal, tax, financial or other professional advisers in respect of any financial instruments mentioned in this website prior to entering into any transaction.

Risk Warning: Leveraged Precious Metals trading on margin carries significant risks and is not suitable for all investors. Please be sure to make investments within your own tolerance after fully understand the risks involved.

Registered & Business Address: Room 1905-1906, 19/F, Eastern Commercial Centre, 395-399 Hennessy Road, Hong Kong

Aspire Global Company Limited is not available to provide services for the residents of certain jurisdictions such as Afghanistan, the United States of America, the Islamic Republic of Iran, North Korean.

Web Design by YSD